Spero Therapeutics Files 8-K Report
Ticker: SPRO · Form: 8-K · Filed: May 28, 2025 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Spero Therapeutics filed an 8-K, likely containing financial updates and other disclosures.
AI Summary
On May 28, 2025, Spero Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates Spero Therapeutics is providing updated financial statements and potentially disclosing other material information to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information indicating immediate or significant risk.
Key Numbers
- 0001701108 — Central Index Key (Identifies Spero Therapeutics, Inc. in SEC filings.)
- 001-38266 — SEC File Number (Unique identifier for Spero Therapeutics, Inc.'s filings.)
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- 0001701108 (company) — Central Index Key
- 001-38266 (company) — SEC File Number
- May 28, 2025 (date) — Date of Report
FAQ
What specific 'Other Events' are disclosed in this 8-K filing?
The provided text does not specify the details of the 'Other Events' beyond listing it as an item in the 8-K.
What are the key financial statements included in this filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific statements are not detailed in the provided text.
Does the filing mention any new material agreements or changes in executive management?
The provided text does not contain information about new material agreements or changes in executive management.
What is the purpose of the 'Regulation FD Disclosure' mentioned in the filing?
A Regulation FD Disclosure is typically made to prevent selective disclosure of material nonpublic information, ensuring all investors receive information simultaneously.
What is Spero Therapeutics, Inc.'s primary business sector?
Spero Therapeutics, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' sector, with SIC code 2834.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding Spero Therapeutics, Inc. (SPRO).